Phase I Clinical Trial of RC19D2 Cell Injection in the Treatment of Diffuse Large B-cell Lymphoma

NCT06047197 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

25

Enrollment

INDUSTRY

Sponsor class

Conditions

Recurrent Diffuse Large B-Cell Lymphoma
Refractory Diffuse Large B-cell Lymphoma

Interventions

BIOLOGICAL: RC19D2 cell injection

Sponsor

Beijing Yongtai Ruike Biotechnology Company Ltd